Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
epilepsy
Biotech
Angelini pens $360M biobucks pact for ph. 1 brain disorder drug
Italy’s Angelini Pharma has signed a $360 million biobucks pact centered on a phase 1-stage brain health drug from South Korea’s Cureverse.
James Waldron
Oct 21, 2024 10:04am
Lundbeck signs $2.5B check for Longboard and its epilepsy med
Oct 14, 2024 8:30am
Praxis epilepsy drug reduces seizures in phase 2 trial
Sep 3, 2024 10:21am
Addex stock rises after Indivior offers up to $300M for compound
Aug 27, 2024 10:50am
Ovid halts preclinical work, IV program after soticlestat fail
Aug 13, 2024 9:15am
Takeda takes $140M loss on failed epilepsy drug, touts FDA run
Jul 31, 2024 9:14am